Drug Patents Expiring in 2039

1. List of Airduo Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000653

(Pediatric)

TEVA PHARM Inhaler
Jun, 2039

(16 years from now)

US11344685 TEVA PHARM Drug delivery device with electronics
Sep, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
M Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

2. List of Anjeso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881663 BAUDAX Method of treating pain in elderly patients with mild renal impairment
Mar, 2039

(16 years from now)

US11458145 BAUDAX Methods of administering intravenous meloxicam in a bolus dose
Mar, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment; Management of moderate-to-severe pain by injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

3. List of Annovera drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765628 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(16 years from now)

US10632066 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(16 years from now)

US10780047 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(16 years from now)

US10918649 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US10925882 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US10940157 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US11529308 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception

Dosage: RING;VAGINAL

More Information on Dosage

4. List of Aristada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273158 ALKERMES INC Aripiprazole dosing strategy
Apr, 2039

(16 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

5. List of Aristada Initio Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273158 ALKERMES INC Aripiprazole dosing strategy
Apr, 2039

(16 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

6. List of Armonair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000653

(Pediatric)

TEVA PHARM Inhaler
Jun, 2039

(16 years from now)

US11344685 TEVA PHARM Drug delivery device with electronics
Sep, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

7. List of Baqsimi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765602 ELI LILLY AND CO Medication delivery systems and methods
Sep, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jul 24, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 24 July, 2019

Treatment: NA

Dosage: POWDER;NASAL

More Information on Dosage

8. List of Bylvay drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10975046 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11365182 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2026
Orphan Drug Exclusivity (ODE) Jul 20, 2028

Drugs and Companies using ODEVIXIBAT ingredient

NCE-1 date: July, 2025

Market Authorisation Date: 20 July, 2021

Treatment: Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage

9. List of Caplyta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695345 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(16 years from now)

US11052084 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Aug, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 20, 2024
New Indication (I) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 20 December, 2019

Treatment: Treatment of schizophrenia; Treatment of bipolar depression mediated by the 5-ht2a receptor, serotonin transporter, and/or dopamine d1/d2 signaling pathways; Treatment of schizophrenia mediated by the 5-ht2a receptor, serotonin transporter, and/or dopamine d1/d2 signaling pathways

Dosage: CAPSULE;ORAL

More Information on Dosage

10. List of Cuvrior drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10988436 ORPHALAN Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
May, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11072577 ORPHALAN Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
May, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 28, 2025

Drugs and Companies using TRIENTINE TETRAHYDROCHLORIDE ingredient

Market Authorisation Date: 28 April, 2022

Treatment: A method for the treatment of adult patients with stable wilson’s disease who are de-coppered and tolerant to penicillamine

Dosage: TABLET;ORAL

More Information on Dosage

11. List of Dexycu Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11097061 EYEPOINT PHARMS Systems, kits and methods for loading and delivering a small volume dose from a syringe
Jun, 2039

(16 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: A method of loading medication into a syringe and delivering the medication to a treatment site

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage

12. List of Dhivy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033521 AVION PHARMS Levodopa fractionated dose composition and use
Mar, 2039

(16 years from now)

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Market Authorisation Date: 12 November, 2021

Treatment: Treatment of parkinson's disease; Method of treating parkinson's disease by orally administering segments of a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, each segment having carbidopa—6.25 mg/levodopa—25 mg; Method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg

Dosage: TABLET;ORAL

More Information on Dosage

13. List of Elcys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653719 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10918662 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10933089 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10912795 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10905714 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10478453 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10583155 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10905713 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US11510941 EXELA PHARMA NA
Jan, 2039

(15 years from now)

US11510942 EXELA PHARMA NA
Jan, 2039

(15 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 April, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of ELCYS before it's patent expiration?
More Information on Dosage

14. List of Elucirem drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10973934 GUERBET Gadolinium bearing PCTA-based contrast agents
Aug, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 21, 2027

Drugs and Companies using GADOPICLENOL ingredient

NCE-1 date: September, 2026

Market Authorisation Date: 21 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

15. List of Epidiolex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11207292 GW RES LTD Cannabidiol preparations and its uses
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2023
Orphan Drug Exclusivity (ODE) Jul 31, 2027
New Patient Population (NPP) Jul 31, 2023

Drugs and Companies using CANNABIDIOL ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 28 September, 2018

Treatment: Use for the treatment of seizures associated with dravet syndrome; Use for the treatment of seizures associated with tuberous sclerosis complex; Use for the treatment of seizures associated with lennox-gastaut syndrome

Dosage: SOLUTION;ORAL

How can I launch a generic of EPIDIOLEX before it's patent expiration?
More Information on Dosage

16. List of Fotivda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11504365 AVEO PHARMS NA
Nov, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 10, 2026

Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient

NCE-1 date: March, 2025

Market Authorisation Date: 10 March, 2021

Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally for 21 days followed by no drug for 7 days

Dosage: CAPSULE;ORAL

More Information on Dosage

17. List of Galafold drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357784 AMICUS THERAP US Use of migalastat for treating Fabry disease in pregnant patients
Feb, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023
Orphan Drug Exclusivity (ODE) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

How can I launch a generic of GALAFOLD before it's patent expiration?
More Information on Dosage

18. List of Gavreto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11273160 GENENTECH INC RET inhibitor for use in treating cancer having a RET alteration
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 4, 2025
Orphan Drug Exclusivity (ODE) Sep 4, 2027

Drugs and Companies using PRALSETINIB ingredient

NCE-1 date: September, 2024

Market Authorisation Date: 04 September, 2020

Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test

Dosage: CAPSULE;ORAL

More Information on Dosage

19. List of Igalmi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792246 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(16 years from now)

US11517524 BIOXCEL NA
Jun, 2039

(16 years from now)

US11478422 BIOXCEL Film formulations containing dexmedetomidine and methods of producing them
Jun, 2039

(16 years from now)

US11497711 BIOXCEL NA
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 5, 2025

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2022

Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual administration

Dosage: FILM;BUCCAL, SUBLINGUAL

More Information on Dosage

20. List of Ingrezza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11026931 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's patent expiration?
More Information on Dosage

21. List of Inrebic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11400092 IMPACT Methods of treating myeloproliferative disorders
Sep, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 16, 2026
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treating adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis, monitoring thiamine levels and administering thiamine or a thiamine equivalent

Dosage: CAPSULE;ORAL

More Information on Dosage

22. List of Katerzia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799453 AZURITY Amlodipine formulations
Apr, 2039

(16 years from now)

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: NA

Dosage: SUSPENSION;ORAL

How can I launch a generic of KATERZIA before it's patent expiration?
More Information on Dosage

23. List of Konvomep drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10751333 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(16 years from now)

US11103492 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(16 years from now)

Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient

Market Authorisation Date: 30 August, 2022

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage

24. List of Lyvispah drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792262 AMNEAL Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
Jul, 2039

(16 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 22 November, 2021

Treatment: Method for treating spasticity

Dosage: GRANULES;ORAL

More Information on Dosage

25. List of Mounjaro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: May, 2026

Market Authorisation Date: 13 May, 2022

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

26. List of Norepinephrine Bitartrate In 0.9% Sodium Chloride drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10888534 INFORLIFE Storage stable ready-to-use norepinephrine aqueous solutions in flexible plastic bags
Apr, 2039

(16 years from now)

Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient

Market Authorisation Date: 15 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

27. List of Nouress drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10653719 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10912795 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10918662 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10583155 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10478453 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10933089 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10905713 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10905714 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10493051 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(16 years from now)

US11045438 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(16 years from now)

US10543186 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(16 years from now)

US10702490 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(16 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need thereof

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

28. List of Nurtec Odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724 BIOHAVEN IRELAND Rimegepant for CGRP related disorders
Mar, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 27, 2025
New Indication (I) May 27, 2024

Drugs and Companies using RIMEGEPANT SULFATE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 27 February, 2020

Treatment: Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

29. List of Orladeyo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10662160 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11117867 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 3, 2027
New Chemical Entity Exclusivity (NCE) Dec 3, 2025

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL

More Information on Dosage

30. List of Ozobax drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610502 METACEL PHARMS LLC Oral baclofen solutions
Aug, 2039

(16 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 18 September, 2019

Treatment: Treatment of spasticity

Dosage: SOLUTION;ORAL

How can I launch a generic of OZOBAX before it's patent expiration?
More Information on Dosage

31. List of Pedmark drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11510984 FENNEC PHARMS INC Anhydrous sodium thiosulfate and formulations thereof
Jul, 2039

(16 years from now)

US11291728 FENNEC PHARMS INC Anhydrous sodium thiosulfate and formulations thereof
Jul, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 20, 2025

Drugs and Companies using SODIUM THIOSULFATE ingredient

Market Authorisation Date: 20 September, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PEDMARK before it's patent expiration?
More Information on Dosage

32. List of Pemazyre drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11466004 INCYTE CORP Solid forms of an FGFR inhibitor and processes for preparing the same
May, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 17, 2025
Orphan Drug Exclusivity (ODE) Apr 17, 2027
New Indication (I) Aug 26, 2025

Drugs and Companies using PEMIGATINIB ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering once daily a tablet containing about 0.5 mg to about 10 mg of pemigatinib; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib qd for 14 days then not administering pemigatinib for 7 days in a 21-day cycle; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to about 20 mg

Dosage: TABLET;ORAL

More Information on Dosage

33. List of Potassium Phosphates drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632150 CMP DEV LLC Potassium phosphates composition for injection
Apr, 2039

(16 years from now)

Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient

Market Authorisation Date: 19 September, 2019

Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

34. List of Proair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11344685 TEVA BRANDED PHARM Drug delivery device with electronics
Sep, 2039

(16 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

35. List of Qvar Redihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792447 NORTON WATERFORD Breath actuated inhaler
Jan, 2039

(16 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

36. List of Radicava Ors drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241416 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(16 years from now)

US10987341 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(16 years from now)

US11478450 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 12, 2025

Drugs and Companies using EDARAVONE ingredient

Market Authorisation Date: 12 May, 2022

Treatment: Treatment of amyotrophic lateral sclerosis

Dosage: SUSPENSION;ORAL

More Information on Dosage

37. List of Rezlidhia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10532047 RIGEL PHARMS INC Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(16 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11376246 RIGEL PHARMS INC Inhibiting mutant IDH-1
May, 2039

(16 years from now)

US11497743 RIGEL PHARMS INC Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
May, 2039

(16 years from now)

US10959994 RIGEL PHARMS INC Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(16 years from now)

US11013734 RIGEL PHARMS INC Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
May, 2039

(16 years from now)

US11013733 RIGEL PHARMS INC Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
May, 2039

(16 years from now)

Drugs and Companies using OLUTASIDENIB ingredient

Market Authorisation Date: 01 December, 2022

Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml)

Dosage: CAPSULE;ORAL

More Information on Dosage

38. List of Sotalol Hydrochloride drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799138 ALTATHERA PHARMS LLC Method of administering sotalol IV/switch
Apr, 2039

(16 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 02 July, 2009

Treatment: Use for loading dose in patients with symptomatic afib/afl who are currently in sinus rhythm or for the treatment of life-threatening ventricular tachycardia

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

39. List of Sympazan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541002 OTTER PHARMS NA
Sep, 2039

(16 years from now)

Drugs and Companies using CLOBAZAM ingredient

Market Authorisation Date: 01 November, 2018

Treatment: Method of treating seizures

Dosage: FILM;ORAL

More Information on Dosage

40. List of Testosterone Cypionate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311554 SLAYBACK PHARMA LLC Pharmaceutical compositions of testosterone
Mar, 2039

(16 years from now)

Drugs and Companies using TESTOSTERONE CYPIONATE ingredient

Market Authorisation Date: 02 June, 2022

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR

More Information on Dosage

41. List of Tibsovo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980788 SERVIER Therapy for treating malignancies
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 20, 2023
Orphan Drug Exclusivity (ODE) Aug 25, 2028
New Indication (I) May 25, 2025

Drugs and Companies using IVOSIDENIB ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 20 July, 2018

Treatment: A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; Treating newly diagnosed acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; Treating relapsed/refractory acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal

Dosage: TABLET;ORAL

How can I launch a generic of TIBSOVO before it's patent expiration?
More Information on Dosage

42. List of Trudhesa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11185497 IMPEL NEUROPHARMA Intranasal delivery of dihydroergotamine by precision olfactory device
Jan, 2039

(15 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 2, 2024

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Market Authorisation Date: 02 September, 2021

Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

43. List of Upneeq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11311515 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(16 years from now)

US11324722 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(16 years from now)

US11103482 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(16 years from now)

US10940138 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(16 years from now)

US10799481 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(16 years from now)

US10814001 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(16 years from now)

US10898573 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(16 years from now)

US11541036 RVL PHARMS NA
Dec, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jul 8, 2023

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 July, 2020

Treatment: Method of treating blepharoptosis

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

44. List of Vabomere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11376237 REMPEX Methods of treating bacterial infections
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 29, 2022
Generating Antibiotic Incentives Now (GAIN) Aug 29, 2027

Drugs and Companies using MEROPENEM; VABORBACTAM ingredient

NCE-1 date: August, 2026

Market Authorisation Date: 29 August, 2017

Treatment: Treatment of complicated urinary tract infections (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli,klebsiella pneumonia,enterobacter cloacae species complex with meropenem & vaborbactam as specified

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

45. List of Vuity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11285134 ABBVIE INC Presbyopia treatments
Apr, 2039

(16 years from now)

US10610518 ABBVIE INC Presbyopia treatments
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 28, 2024

Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2021

Treatment: Use of vuity for the treatment of presbyopia in adults

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

46. List of Xarelto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events
Jan, 2039

(16 years from now)

US10828310

(Pediatric)

JANSSEN PHARMS Reducing the risk of cardiovascular events
Jul, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Aug 23, 2024
M Mar 10, 2023
Pediatric Exclusivity (PED) Apr 11, 2023

Drugs and Companies using RIVAROXABAN ingredient

Market Authorisation Date: 01 July, 2011

Treatment: Reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily; Reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily

Dosage: TABLET;ORAL

How can I launch a generic of XARELTO before it's patent expiration?
More Information on Dosage

47. List of Yupelri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11484531 MYLAN IRELAND LTD NA
Oct, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 9, 2023

Drugs and Companies using REVEFENACIN ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 09 November, 2018

Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: SOLUTION;INHALATION

How can I launch a generic of YUPELRI before it's patent expiration?
More Information on Dosage

48. List of Zimhi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11027072 ADAMIS PHARMS CORP Emergency devices
May, 2039

(16 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 October, 2021

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

List of large molecules

1. List of Eylea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US10973879 REGENERON PHARMACEUTICALS, INC. Use of a VEGF antagonist to treat angiogenic eye disorders
May, 2039

(16 years from now)

US11160918 REGENERON PHARMACEUTICALS, INC. Medical device packaging and related methods
Jul, 2039

(16 years from now)

Ingredients: AFLIBERCEPT

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in